IPF-associated cough affects up to 80% of patients with IPF, substantially impairing their quality of life; consequently, ...
The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...
SAN DIEGO -- Two novel drugs improved lung function in idiopathic pulmonary fibrosis (IPF) in a pair of phase IIa trials, researchers reported here. In an open-label, single-arm trial of 46 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results